Obesity

A loss of as little as 2-3% of a patient’s total body weight can help them achieve better blood glucose levels.

Patients who have obesity but don't have diabetes may now reap the benefits of using a GLP-1 receptor agonist.

A woman, 72 years of age, type 2 diabetes, obesity, taking metformin, GLP1, ARB, and antidepressant (SSRI). Lost 20% total body weight in the past year. Recently complaining of dizziness and weakness. Glucose levels in the 60’s at home, at which time had symptoms of hypoglycemia. Glucose-lowering medications (metformin and GLP-1) were stopped. Continued to complain of dizziness and weakness especially in the morning.

Contrary to previous studies, new research finds SGLT-2i more effective for weight loss than GLP-1 RAs as add-on therapy to Metformin. 

Analysis finds that for every increase of a BMI unit, there was a 5-15% excess risk of developing severe COVID-19. 

Study examines the effect of Mediterranean or low carb diet on weight, waist circumference and blood glucose in patients with obesity. 

Study identifies multiple risk factors for type 2 diabetes, including insomnia, that need to be incorporated into diabetes prevention strategies.

Approximately 30% to 53% of diabetes mellitus cases in the United States can be attributed to obesity. 

The new approval of Wegovy™ is for a current medication, semaglutide, but more than doubling the standard dose for diabetes treatment. 

SURPASS-4 is a randomized controlled trial of tirzepatide once a week vs. insulin glargine once a day in type 2 diabetes patients with high cardiovascular risk.